//
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
Nitrosative stress drives heart failure with preserved ejection fraction
Can We Use the Intrinsic Left Ventricular Delay (QLV) to Optimize the Pacing Configuration for Cardiac Resynchronization Therapy With a Quadripolar Left Ventricular Lead?
Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review
Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure
HFpEF: From Mechanisms to Therapies
Functional Impairment and Medication Burden in Adults With Heart Failure
Heart Failure With Preserved Ejection Fraction in the Young